What if the chemistry created by neurological disease could help activate medicine precisely where it is needed? In this episode of Tech Talks Daily, I speak with Sara Isbell, neuroscientist and co-founder of Enabled Therapeutics, about a proposed approach to one of medicine's most stubborn problems: delivering effective drugs to diseased brain tissue without exposing healthy areas to the same activity. Sara explains how the blood-brain barrier prevents many promising compounds from reaching the brain. When drugs do enter, they may spread across healthy and diseased regions alike, creating a difficult balance between therapeutic benefit and unwanted effects. We hear how an unexpected laboratory result led Sara and her co-founder to investigate whether pathological oxidative stress could convert a precursor molecule into a biologically active compound near the affected tissue. Sara describes this as pathology-gated therapeutic activation, where disease-associated chemistry provides the trigger that turns the medicine on. This remains developing science. At the time of recording, Enabled Therapeutics was preparing its first peer-reviewed manuscript and seeking partners to support further studies. Sara explains why reproducible evidence, regulatory guidance, and careful laboratory validation must determine whether the hypothesis advances. We also discuss how AI helps small biotechnology teams review literature, organize regulatory materials, connect ideas across scientific disciplines, and identify possible hypotheses. However, Sara offers an important reminder: AI can propose possibilities, but nature and experimental evidence decide what is true. Could following one unexpected result eventually offer researchers another way to approach neurological disease? Listen to the conversation and share your thoughts with me.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related